secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coya Therapeutics, Inc. (COYA)
CIK:        0001835022
Form:       8-K
Filed at:   2026-08-11T12:03:41+00:00
Accession:  0001193125-26-343473
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coya Q2 2026 net loss $6.6M; cash $43.2M funds ALS trial into 2H27
------------------------------------------------------------------

- Net loss $6.6M for Q2 2026 vs $6.1M in Q2 2025; R&D up $1.3M to $5.0M on COYA 302 ALS trial costs.
- Cash and equivalents $43.2M at June 30, 2026, expected to fund operations past Phase 2 ALSTARS readout into 2H 2027.
- FDA granted Fast Track Designation for COYA 302 in ALS; first cohort advanced into 24-week blinded active treatment extension.
- Collaboration revenue flat at $0.2M under DRL agreement; G&A down $0.6M to $2.3M.
- On track to complete ALSTARS enrollment in 2H 2026 and report topline data in Q1 2027; Phase 2 FTD study to initiate in 2H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835022/000119312526343473/0001193125-26-343473-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835022/000119312526343473/coya-20260811.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-343473

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer